Mon, Nov 04, 2024
Despite this setback, Sun Pharma’s stock has rallied 43 per cent year-to-date, fueled by growth in speciality drugs, emerging markets, and domestic sales.
More >
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
